Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes
- 1 January 2002
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 300 (1), 298-304
- https://doi.org/10.1124/jpet.300.1.298
Abstract
The purpose of the study was to elucidate human intestinal cytochrome P450 isoform(s) involved in the metabolism of an antihistamine, ebastine, having two major pathways of hydroxylation andN-dealkylation. The ebastine dealkylase in human intestinal microsomes was CYP3A4, based on the inhibition studies with antibodies against CYP1A, CYP2A, CYP2C, CYP2D, CYP2E, and CYP3A isoforms and their selective inhibitors. However, ebastine hydroxylase could not be identified. We then examined the inhibitory effects of anti-CYP4F antibody and 17-octadecynoic acid, an inhibitor of the CYP4 family, on ebastine hydroxylation in intestinal microsomes, since CYP4F was recently found to be the predominant ebastine hydroxylase in monkey intestine; and a novel CYP4F isoform (CYP4F12), also capable of hydroxylating ebastine, was found to exist in human intestine. However, the inhibitory effects were only partial (about 20%) and thus it was thought that, although human CYP4F was involved in ebastine hydroxylation, another predominant enzyme exists. Further screening showed that the hydroxylation was inhibited by arachidonic acid. CYP2J2 was selected as a candidate expressed in the intestine and closely related to arachidonic acid metabolism. The catalytic activity of recombinant CYP2J2 was much higher than that of CYP4F12. Anti-CYP2J antibody inhibited the hydroxylation to about 70% in human intestinal microsomes. These results demonstrate that CYP2J2 is the predominant ebastine hydroxylase in human intestinal microsomes. Thus, the present paper for the first time indicates that, in human intestinal microsomes, both CYP2J and CYP4F subfamilies not only metabolize endogenous substrates but also are involved in the drug metabolism.Keywords
This publication has 18 references indexed in Scilit:
- cDNA Cloning and Expression of a Novel Cytochrome P450 (CYP4F12) from Human Small IntestineBiochemical and Biophysical Research Communications, 2001
- Expression of Biotransformation Enzymes in Human Fetal Olfactory Mucosa: Potential Roles in Developmental ToxicityToxicology and Applied Pharmacology, 2000
- Computer-Assisted Comparison of the Structural and Electronic Dispositions of Ebastine and TerfenadineDrug Safety, 1999
- Multiple forms of human P450 expressed in Saccharomyces cerevisiae: Systematic characterization and comparison with those of the ratBiochemical Pharmacology, 1996
- Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomesArchives of Biochemistry and Biophysics, 1995
- Cloning and expression of a novel form of leukotriene B4 ω‐hydroxylase from human liverFEBS Letters, 1994
- Progesterone metabolism in recombinant yeast simultaneously expressing bovine cytochromes P450cl7 (CYP17A1) and P450c21 (CYP21B1) and yeast NADPH-P450 oxidoreductasePharmacogenetics, 1991
- Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvationArchives of Biochemistry and Biophysics, 1990
- Expression of Rat NADPH-Cytochrome P-450 Reductase cDNA inSaccharomyces cerevisiaeDNA, 1986
- Expression of Rat Liver Cytochrome P-450MC cDNA inSaccharomyces cerevisiaeDNA, 1985